FDA Mandates New Labeling for GLP-1 Drugs Citing Rare Vision Loss Risk
The FDA has required all GLP-1 medication manufacturers to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. This update affects popular drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. While the condition is rare, the FDA found a slightly higher incidence rate in long-term users compared to placebo groups. Manufacturers have expressed confidence in their drugs' overall safety profiles, noting that the benefits outweigh the risks.
Key points
- The FDA announced on Monday that all GLP-1 receptor agonist medications must include a warning about NAION in their labeling.
- NAION, often described as an 'eye stroke,' involves reduced blood flow to the optic nerve and can result in sudden, painless vision loss or permanent blindness.
- The FDA’s analysis of over 125 clinical trials found NAION occurred in approximately 6 per 100,000 patients taking GLP-1s for at least one year, compared to fewer than 4 per 100,000 in control groups.
- Symptoms include blurred vision, blind spots, and distorted colors; patients are advised to contact healthcare providers immediately if these occur.
- The warning applies to all GLP-1 drugs, including those used for diabetes and weight loss, such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro.
Background
Recent months have seen increased scrutiny of GLP-1 side effects, including reports of muscle loss, bone density issues, and nausea. While earlier concerns focused on metabolic and musculoskeletal effects, this new warning highlights potential neurological and ophthalmic risks. A 2025 study tracking nearly 175,000 patients also suggested a doubled risk of NAION after two years of treatment, contributing to the FDA’s decision.
How outlets are covering it
The FDA emphasizes the need for patient awareness based on clinical and post-marketing data. In contrast, Eli Lilly and Novo Nordisk maintain that the data do not establish a direct cause-and-effect relationship. Novo Nordisk stated it remains confident in the benefit-risk profile of its drugs, while Lilly noted it is evaluating the update. Citi analyst Geoff Meacham suggested the warning might cause temporary concern but that the substantial health benefits of GLP-1s should limit changes in prescribing practices. The European Medicines Agency had previously flagged a similar risk, estimating it affects up to 1 in 10,000 users of semaglutide.
Why it matters
This regulatory action affects millions of patients using GLP-1 drugs for weight loss and diabetes. It highlights the ongoing balance between the significant therapeutic benefits of these medications and rare but serious adverse effects. The warning may influence patient decisions and provider prescribing habits, particularly as long-term usage data continues to emerge.
What to watch
Manufacturers will update drug labels to include the NAION warning. Healthcare providers may monitor patients for visual symptoms more closely. Further studies may be conducted to clarify the causal relationship between GLP-1 use and NAION. The FDA may continue to review post-marketing safety data as more cases are reported.
- FDA tells GLP-1 makers to warn of potential vision loss side effect The Washington Post
- US FDA orders new eye risk warnings for Ozempic, Zepbound CNN
- FDA adds rare vision-loss warning to popular GLP-1 drugs AP News
- US regulator orders blindness risk warning on obesity drugs Financial Times
- FDA warns GLP-1 drugs carry potential risk of rare eye condition STAT
Want the full story? Read the original reporting
Read on The Washington Post